csl usa hizentra human normal immunoglobulin 20% solution for subcutaneous injection vials
csl behring australia pty ltd - human immunoglobulin g, quantity: 200 g/l - injection - excipient ingredients: polysorbate 80; proline; hydrochloric acid; sodium hydroxide; water for injections - 1 indications and usage hizentra is an immune globulin subcutaneous (human) (igsc), 20% liquid indicated for the treatment of the following conditions: 1.1 primary immunodeficiency (pi) hizentra is indicated as replacement therapy for primary humoral immunodeficiency (pi) in adults and pediatric patients 2 years of age and older. this includes, but is not limited to, the humoral immune defect in congenital agammaglobulinemia, common variable immunodeficiency, x-linked agammaglobulinemia, wiskott-aldrich syndrome, and severe combined immunodeficiencies. 1.2 chronic inflammatory demyelinating polyneuropathy (cidp) hizentra is indicated for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (cidp) as maintenance therapy to prevent relapse of neuromuscular disability and impairment. limitations of use: hizentra maintenance therapy in cidp has been systematically studied for 6 months and for a further 12 months in a follow-up study. maintenance therapy beyond these periods should be individualized based upon the patient?s response and need for continued therapy [see dosage and administration (2)].
cobactan la for cattle 7.5 % inj. susp. s.c. vial
intervet international b.v. - cefquinome sulfate - suspension for injection - 7,5 % - cefquinome sulfate - cefquinome - cattle
cobactan suspension for injection
intervet international b.v, netherlands - cefquinome sulphate - suspension for injection - 25 mg/ml
lumicef subcutaneous injection 210 mg syringe
kyowa kirin malaysia sdn. bhd. - brodalumab -
needle, subcutaneous injection/infusion port
smiths medical australasia pty ltd - 17180 - needle, subcutaneous injection/infusion port - the huber needle infusion set is a device with a non-coring right angle needle intended for insertion into the septum of a subcutaneously implanted port and for the infusion of fluids and drugs, as well as blood sampling into the port.
peripheral vascular/subcutaneous catheter
becton dickinson pty ltd - 61650 - peripheral vascular/subcutaneous catheter - intended to be inserted into a patient's peripheral vascular system for short term use (less than 30 days) to sample blood, monitor blood pressure, or administer fluids; or for subcutaneous administration of fluids and medications. these devices may be used for any patient population with consideration given to adequacy of vascular anatomy or subcutaneous tissue, appropriateness for solutions being infused and duration of therapy.
safety subcutaneous infusion sets - needle, subcutaneous injection/infusion port
epic medical pty ltd - 17180 - needle, subcutaneous injection/infusion port - the safety subcutaneous infusion set consists of a needle, tubing and syringe port, connected as a system to enable subcutaneous infusion of medication administered by an external infusion device.
needle, subcutaneous injection/infusion port
clinect pty ltd - 17180 - needle, subcutaneous injection/infusion port - manufacturer's intended purpose: infusion port for subcutaneous administration of a medicine
needle, subcutaneous injection/infusion port
medtronic australasia pty ltd - 17180 - needle, subcutaneous injection/infusion port - the i-port advance? injection port is indicated for patients who administer, or to whom is administered, multiple daily subcutaneous injections of physician prescribed medications, including insulin.
needle, subcutaneous injection/infusion port
convatec australia pty ltd - 17180 - needle, subcutaneous injection/infusion port - infusion port for subcutaneous administration of a medicine.